Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CEL | P19835 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3546001 | 0.96 | SIGMAR1 (0.47) | CYP1A2SIGMAR1KDM4ETDP1CEL | |
| SCHEMBL3543149 | 0.94 | SIGMAR1 (0.50) | CYP1A2SIGMAR1KDM4ETDP1CEL | |
| SCHEMBL3550474 | 0.94 | SIGMAR1 (0.50) | CYP1A2SIGMAR1KDM4ETDP1CEL | |
| SCHEMBL1524646 | 0.91 | KDM4E (0.41) | CYP1A2SIGMAR1KDM4ETDP1MAPK1 | |
| SCHEMBL1524564 | 0.89 | KDM4E (0.38) | CYP1A2SIGMAR1KDM4ETDP1MAPK1 | |
| SCHEMBL2141114 | 0.89 | MAPK1 (0.38) | CYP1A2KDM4ETDP1MAPK1HSD17B10 | |
| SCHEMBL2136195 | 0.84 | MAPK1 (0.38) | CYP1A2SIGMAR1KDM4ETDP1MAPK1 | |
| SCHEMBL2138060 | 0.82 | MAPK1 (0.37) | SIGMAR1KDM4ETDP1MAPK1HSD17B10 | |
| SCHEMBL11075927 | 0.82 | MAPK1 (0.37) | SIGMAR1KDM4ETDP1MAPK1HSD17B10 | |
| SCHEMBL3538805 | 0.80 | KDM4E (0.33) | KDM4ETDP1MAPK1SLC18A3HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101087772-B | High-purity alicyclic diepoxy compound and preparation method thereof | DAICEL CHEM | 2012-05-09 | — | — | CN | disclosed |
| CN-1934098-B | High-purity alicyclic epoxy compound, process for producing the same, curable epoxy resin composition, cured article thereof, and use | DAICEL CHEM | 2012-04-25 | — | — | CN | disclosed |
| US-7732627-B2 | High-purity cycloaliphatic diepoxy compound and preparation process thereof | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20080045729-A1 | High-Purity Cycloaliphatic Diepoxy Compound and Preparation Process Thereof | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| EP-1834949-A1 | HIGH-PURITY ALICYCLIC DIEPOXY COMPOUND AND PROCESS FOR PRODUCING THE SAME | Daicel Chemical Industries, Ltd. (JP) | 2007-09-19 | — | — | EP | disclosed |
| US-20070179256-A1 | High-purity alicyclic epoxy compound, process for production of the same, curable epoxy resin composition, cured product thereof, and application thereof | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| CN-1934098-A | High-purity alicyclic epoxy compound, process for producing the same, curable epoxy resin composition, cured article thereof, and use | DAICEL CHEM (JP) | 2007-03-21 | — | — | CN | disclosed |
| EP-1726588-A1 | HIGH-PURITY ALICYCLIC EPOXY COMPOUND, PROCESS FOR PRODUCING THE SAME, CURABLE EPOXY RESIN COMPOSITION, CURED ARTICLE THEREOF, AND USE | Daicel Chemical Industries, Ltd. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045729-A1 | High-Purity Cycloaliphatic Diepoxy Compound and Preparation Process Thereof | DUOX2, SQLE, HPD | CYP1A2 434/4885SIGMAR1 3854/4885KDM4E 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.